Journal List > J Korean Rheum Assoc > v.17(3) > 1003730

TOOLS
Song: Light and Shadow in the Treatment of Gout
Original Article

J Korean Rheum Assoc 2010;17(3):227-229.

Published online: 23 September 2010

DOI: https://doi.org/10.4078/jkra.2010.17.3.227

Light and Shadow in the Treatment of Gout

Jung-Soo Song

Department of Rheumatology, Internal Medicine, Chung-Ang University School of Medicine, Seoul, Korea

Received 9 August 201023 August 2010       Accepted 23 August 2010

Copyright © 2010 The Korean Rheumatism Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

1). Wallace KL., Riedel AA., Joseph-Ridge N., Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004. 31:1582–7.
2). Mikuls TR., Farrar JT., Bilker WB., Fernandes S., Schumacher HR Jr., Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005. 64:267–72.
crossref
3). Annemans L., Spaepen E., Gaskin M., Bonnemaire M., Malier V., Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008. 67:960–6.
crossref
4). Rho YH., Choi SJ., Lee YH., Ji JD., Choi KM., Baik SH, et al. Prevalence of the metabolic syndrome in patients with gout. J Korean Rheum Assoc. 2004. 10:349–57.
5). Rathmann W., Funkhouser E., Dyer AR., Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998. 8:250–61.
6). Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998. 57:509–10.
crossref
7). Lee J., Sparrow D., Vokonas PS., Landsberg L., Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol. 1995. 142:288–94.
8). Choi HK., Atkinson K., Karlson EW., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch Intern Med. 2005. 165:742–8.
9). Son KM., Seo YI., Kim IJ., Bae YD., Jung YO., Cha MJ, et al. Adherence to uric acid lowering agent of gouty patients. J Korean Rheum Assoc. 2010. 17:162–7.
crossref
10). Emmerson BT. The management of gout. Hochberg MC, Silman AJ, Smolen JS, Weinblattv ME, Weisman MH, editors. eds.Rheumatology. 4th ed.p. 1839–46. Philadelphia, Elsevier;2008.
11). Schumacher HR., Chen LX. Gout and other crystal-associated arthropathies. In:. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. eds.Harrison's principles of internal medicine. 17th ed.p. 2165–9. New York, McGraw-Hill;2008.
TOOLS
Similar articles